• Quotes
  • Shortcuts
The Executive's Internet
Wed, Aug 5th
editor corner icon Editor's Corner | Archive
Planning for an aging population: Experts discuss how an aging population will affect many facets of our societies—and will require new partnerships among all types of stakeholders. Patricia
site of the day icon Site of the Day | Archive
Find 2000+ courses from schools like Stanford and Yale - no application required.



Setup News Ticker
Searching for 'Covid-19 cases'. (Return)

Yahoo BusinessAug 04, 2020
Novavax's COVID-19 Vaccine Has an Edge Over Rivals, Says 5-Star Analyst
The coronavirus isn't going away just yet. The number of cases in the US passed 4.5 million, bringing the total number of US deaths to 158K.The need for a vaccine could not be more profound. While the data is alarming, the good news is that with each passing day, a vaccine solution is closer to becoming a reality. There are several candidates in the race hoping to be first to market. B.Riley FBR analyst Mayank Mamtani believes Novavax's (NVAX) vaccine candidate, NVX-CoV2373, could make its way from the back of the pack to the front.Mamtani said, "While acknowledging the 6-8 week lag in terms of time to market entry relative to three leading vaccine candidates from AZ, MRNA, and PFE/BNTX, we highlight the potential of NVX-CoV2373 to demonstrate the most potent immune response, as assessed primarily by neutralizing titers and memory T cell immunity. This, coupled with differentiation on reactogenicity profile, particularly relative to mRNA-based approaches, supports our conviction for '2373 to become the preferred vaccine of choice in the elderly population."Supporting Mamtani's argument that Novavax's offering could become popular with the elderly are the results from another study. In the Phase 3 trial of Novavax's flu vaccine, NanoFlu, which is also based on its adjuvanted nanoparticle vaccine platform, reactogenicity compared favorably to the market leader, Fluzone. In comparison, both Moderna's mRNA-1273 and Pfizer/BNTX's BNT162b1 elicited flu-like symptoms in 75-100% of subjects. Although
EarningsCall Transcript Q2 Inc Corp
CoronavirusVaccine Novavax cases Early White
COVID-19Vaccine Novavax Results positive despite
Stockearnings market Kodak surges beat
TikTokChina Microsoft Trump Lawsuit Claims
CallEarnings Transcript Q2 Inc Corp
ChinaTikTok Lawsuit Claims Steals Kids
DisneyBillion ‘Mulan Pandemic theme Loses
TranscriptEarnings Call Q2 Inc Corp
PandemicDisney nearly coronavirus billion amid

Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
INSEAD Knowledge
International Tax Review
L.S. Starrett News
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC